World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
43243
World Ranking
15359
National Ranking
7745

Overview

Patrick A. Ott is affiliated with Harvard University in the United States. Their research primarily spans the field of Medicine, with a focus on Oncology, Immunology, Molecular Biology, Epidemiology, and Pulmonary and Respiratory Medicine. The main topics of their work include Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses, Melanoma and MAPK Pathways, vaccines and immunoinformatics approaches, Cutaneous Melanoma Detection and Management, and Cancer Genomics and Diagnostics.

Ott has contributed to several recent papers in high-impact journals. These include:

  • Advances in the development of personalized neoantigen-based therapeutic cancer vaccines, 2021, Nature Reviews Clinical Oncology
  • A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer, 2020, Cell
  • Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma, 2021, Nature
  • Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma, 2021, Nature Medicine
  • NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021, 2021, Journal of the National Comprehensive Cancer Network

Their frequent co-authors include:

  • Elizabeth I. Buchbinder
  • F. Stephen Hodi
  • Anita Giobbie-Hurder
  • Osama E. Rahma
  • Catherine J. Wu

Ott regularly publishes in several venues with the highest number of publications appearing in the Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, Cancer Research, Regular and Young Investigator Award Abstracts, and Nature.

Their research topics and fields indicate a strong emphasis on innovative cancer treatments, especially related to immunotherapy. Their involvement in neoantigen vaccine development and personalized therapies reflects a focus on targeted cancer treatment strategies.

Best Publications

  • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

    Michael A. Postow;Jason Chesney;Anna C. Pavlick;Caroline Robert

  • An immunogenic personal neoantigen vaccine for patients with melanoma

    Patrick A. Ott;Zhuting Hu;Derin B. Keskin;Derin B. Keskin;Sachet A. Shukla;Sachet A. Shukla

  • Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

    Razvan Cristescu;Robin Mogg;Mark Ayers;Andrew Albright

  • A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

    Livnat Jerby-Arnon;Parin Shah;Michael S. Cuoco;Christopher Rodman

  • Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

    Scott J. Antonia;José A. López-Martin;Johanna Bendell;Patrick A. Ott

  • Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

    Derin B. Keskin;Annabelle J. Anandappa;Jing Sun;Itay Tirosh

  • Towards personalized, tumour-specific, therapeutic vaccines for cancer

    Zhuting Hu;Patrick A. Ott;Patrick A. Ott;Catherine J. Wu

  • Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

    F Stephen Hodi;Jason Chesney;Anna C Pavlick;Caroline Robert

  • CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

    Patrick A. Ott;F. Stephen Hodi;Caroline Robert

  • T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

    Patrick A. Ott;Yung Jue Bang;Sarina A. Piha-Paul;Albiruni R. Abdul Razak

  • Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

    Padmanee Sharma;Margaret K. Callahan;Petri Bono;Joseph Kim

  • Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

    Douglas B. Johnson;Ryan J. Sullivan;Patrick A. Ott;Matteo S. Carlino

  • Advances in the development of personalized neoantigen-based therapeutic cancer vaccines

    Eryn Blass;Patrick A. Ott

  • A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.

    Patrick A. Ott;Siwen Hu-Lieskovan;Bartosz Chmielowski;Ramaswamy Govindan

  • Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors

    Frank B. Cortazar;Kristen A. Marrone;Megan L. Troxell;Kenneth M. Ralto

  • CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

    Yelena Y. Janjigian;Johanna Bendell;Emiliano Calvo;Joseph W. Kim

  • Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

    Kevin B. Kim;Richard Kefford;Anna C. Pavlick;Jeffrey R. Infante

  • Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.

    Lucie Heinzerling;Patrick A. Ott;F. Stephen Hodi;Aliya N. Husain

  • Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study

    Patrick A. Ott;Elena Elez;Sandrine Hiret;Dong Wan Kim

  • Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results from the KEYNOTE-028 Study

    Patrick A. Ott;Yung Jue Bang;Dominique Berton-Rigaud;Elena Elez

Frequent Co-Authors

F. Stephen Hodi
F. Stephen Hodi Harvard University
Johanna C. Bendell
Johanna C. Bendell Sarah Cannon Research Institute
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Jason J. Luke
Jason J. Luke University of Pittsburgh
Sarina Anne Piha-Paul
Sarina Anne Piha-Paul The University of Texas MD Anderson Cancer Center
Catherine J. Wu
Catherine J. Wu Harvard University
Sachet A. Shukla
Sachet A. Shukla The University of Texas MD Anderson Cancer Center
Nina Bhardwaj
Nina Bhardwaj Icahn School of Medicine at Mount Sinai
Nir Hacohen
Nir Hacohen Harvard University
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn't always mean attending traditional medical school. There are many alternative healthcare roles that offer flexibility and strong job prospects through online study.

For those interested in the administrative side of healthcare, billing and coding classes online can open doors to essential healthcare support positions. These courses are ideal for students who prefer remote work opportunities and wish to start working quickly.

If patient care is your goal, a variety of affordable online nursing programs are available, letting you train for roles as a registered nurse without relocating. Nurses seeking advanced roles can pursue affordable np programs to gain greater autonomy and increased earning potential.

For aspiring nurse leaders or educators, an online phd nursing offers a pathway to the highest levels in the field, supporting careers in research, teaching, and advanced clinical practice.

Each of these online degree options broadens your career outlook, providing opportunities both in direct patient care and essential support services within the U.S. healthcare system.

Best Scientists Citing Patrick A. Ott

Trending Scientists

Recently Published Articles